Definiens, Cernostics Team on Multiplex Cancer Tests | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Definiens and Cernostics today announced that they will collaborate on the development of multiplex molecular diagnostics tests for a variety of cancers.

Danville, Pa.-based Cernostics will use Definiens' Tissue Studio digital pathology technology to develop the tests. The Definiens technology enables pathologists to analyze cancers on the cellular and sub-cellular level, the firms said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.